U.K. House of Commons committee demands more clinical-trial transparency

09/18/2013 | PharmaTimes (U.K.)

A House of Commons Science and Technology Committee report says too many clinical trials remain unregistered and unpublished, and the lack of transparency undermines public trust, slows medical progress and potentially puts patients at risk. The committee does not advocate uncontrolled release of patient-level data, but does urge stronger government action to facilitate sharing of raw clinical-trial data.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY